For patients with metabolic syndrome, is it reasonable to wait for the effect of tirzepatide therapy on their lipid profile prior to starting statin therapy?

While tirzepatide has shown significant improvements in lipid profiles, including reductions in total cholesterol, LDL cholesterol, and triglycerides, and increases in HDL cholesterol, these effects should be considered complementary to, rather than a replacement for, statin therapy.

Yes, it would be reasonable to get a baseline lipid level after optimization of lifestyle factors and other non-lipid lowering therapies (especially glucose-lowering drugs) before starting statins. GLP1 RAs are quite likely to reduce triglyceride levels. However, I always tell patients that they will still need a statin for CV protection (not just lipid lowering). Unless somebody has very low cholesterol (LDLc < 70 with normal TG), statins are indicated for primary prevention. It is unlikely that Tirzepatide will cause this degree of lipid-lowering and patients will still need a statin, which however can be started the next visit depending on patient preference. Some patients do not like starting too many meds at once.

Metabolic syndrome by itself is not an automatic signal to start a statin. However, many patients with metabolic syndrome will benefit from statin therapy, based on usual criteria emphasizing overall ASCVD risk. Given the track record for statin therapy in preventing atherosclerotic events as well as safety compared to recent success with GLP1RAs and tirzepatide, I would prioritize the decision on statin therapy over the initiation of tirzepatide.

If the LDL and fasting levels are above 100 mg/dL, I would start a statin. If you need more risk stratification, you could always check a Calcium Score (ct) to see if the patient has plaque. Alternatively, checking an Apo B level or Lp(a) may help you further risk stratify. Getting a patient to their ideal weight does not portend that the patient will not need a statin.